World Lung 2016

Efficacy and Safety of Necitumumab plus Pembrolizumab in Patients Who Relapsed After Chemotherapy for Metastatic Nonsquamous NSCLC

Conference Correspondent - WCLC 2016 - Lung Cancer

Necitumumab, an epidermal growth factor receptor inhibitor, is approved with gemcitabine and cisplatin for previously untreated advanced squamous non–small-cell lung cancer (NSCLC). Nivolumab, a PD-1 inhibitor, is approved for previously untreated NSCLC, as well as relapsed NSCLC, based on PD-L1 expression. This phase 1b study evaluated combination use of these agents. [ Read More ]

Randomized, Phase 3 Study of First-Line Ceritinib vs Chemotherapy in Patients with ALK-Positive NSCLC (ASCEND-4)

Conference Correspondent - WCLC 2016 - Lung Cancer

Ceritinib is approved for use in patients with advanced ALK-positive non–small-cell lung cancer (NSCLC) who have progressed following treatment with crizotinib. In ASCEND-4, a multicenter randomized trial in previously untreated adult patients, researchers assessed progression-free survival outcomes for ceritinib compared with standard first-line and maintenance chemotherapy. [ Read More ]

Randomized Phase 3 Study of Osimertinib vs Platinum-Pemetrexed for Patients with EGFR T790M-Positive Advanced NSCLC After EGFR-TKI Therapy (AURA3)

Conference Correspondent - WCLC 2016 - Lung Cancer

Osimertinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), is indicated for use in patients with locally advanced or metastatic EGFR T790M-positive non–small-cell lung cancer (NSCLC) who have progressed on or after EGFR-TKI therapy. Researchers compared the efficacy and safety of osimertinib with platinum-based chemotherapy plus pemetrexed in this patient population. [ Read More ]

Atezolizumab as First-Line Therapy for Advanced NSCLC in PD-L1–Selected Patients (BIRCH)

Conference Correspondent - WCLC 2016 - Lung Cancer

Atezolizumab, a humanized anti–PD-L1 monoclonal antibody, is being assessed in a phase 2 study in PD-L1–selected advanced non–small-cell lung cancer (NSCLC) patients. Initial analysis demonstrated a meaningful objective response rate with durable response in chemotherapy-naive first-line and relapsed PD-L1–selected patients. Researchers reported updated efficacy data in these first-line patients. [ Read More ]

Pembrolizumab in Patients with Extensive-Stage Small-Cell Lung Cancer (SCLC): KEYNOTE-028

Conference Correspondent - WCLC 2016 - Lung Cancer

Extensive-stage disease (ED) small-cell lung cancer (SCLC) is characterized by limited treatment options and poor survival after platinum-based chemotherapy. Pembrolizumab, an inhibitor of PD-1, is active and safe in multiple solid tumors. Researchers presented updated safety and efficacy data for patients with ED SCLC who enrolled in KEYNOTE-028. [ Read More ]

First-Line Nivolumab Monotherapy and Nivolumab plus Ipilimumab in Patients with Advanced NSCLC (CheckMate 012)

Conference Correspondent - WCLC 2016 - Lung Cancer

Nivolumab, a PD-1 immune checkpoint inhibitor, has demonstrated superior efficacy relative to docetaxel in patients with advanced non–small-cell lung cancer (NSCLC) who progressed on or after platinum-based chemotherapy regardless of PD-L1 expression. Researchers presented findings from a phase 1 study of nivolumab as first-line therapy for advanced NSCLC. [ Read More ]

Plenary Session 5: Reflections from Giants on Milestones in the Treatment Advances in Lung Cancer—Translational Lung Cancer Research

Conference Correspondent - WCLC 2016 - Lung Cancer

Association of a survival benefit with chemotherapy use for non–small-cell lung cancer (NSCLC) was observed only after the development of cisplatin and platinum doublets. Recent therapeutic advancements in NSCLC and other solid tumors have revolved around the development of immunotherapies that inhibit immune checkpoints, as well as drugs that target driver mutations. [ Read More ]